RARE
NASDAQ · Biotechnology
Ultragenyx Pharmaceutical In
$14.51
+0.01 (+0.07%)
Financial Highlights (FY 2026)
Revenue
701.21M
Net Income
-599,094,092
Gross Margin
83.8%
Profit Margin
-85.4%
Rev Growth
+22.8%
D/E Ratio
3.41
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | 83.8% | 83.8% | 33.1% | 33.1% |
| Operating Margin | -79.5% | -71.5% | 6.2% | 7.5% |
| Profit Margin | -85.4% | -81.2% | 5.8% | 6.1% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 701.21M | 570.97M | 933.24M | 985.63M |
| Gross Profit | 587.61M | 478.47M | 308.73M | 326.06M |
| Operating Income | -557,391,883 | -408,478,702 | 58.15M | 73.93M |
| Net Income | -599,094,092 | -439,039,722 | 54.30M | 59.69M |
| Gross Margin | 83.8% | 83.8% | 33.1% | 33.1% |
| Operating Margin | -79.5% | -71.5% | 6.2% | 7.5% |
| Profit Margin | -85.4% | -81.2% | 5.8% | 6.1% |
| Rev Growth | +22.8% | +22.8% | -2.9% | -7.2% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 567.84M | 567.84M | 244.54M | 228.75M |
| Total Equity | 166.69M | 166.69M | 1.81B | 1.68B |
| D/E Ratio | 3.41 | 3.41 | 0.13 | 0.14 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | -549,083,974 | -424,745,358 | 81.20M | 76.73M |
| Free Cash Flow | — | — | 84.57M | 73.09M |